Skip to main content
. 2018 Nov 1;11:7715–7724. doi: 10.2147/OTT.S178597

Figure 4.

Figure 4

PCAT6 is the target of miR-330-5p.

Notes: (A) Bioinformatics analysis using online tool showed the putative binding sites between miR-330-5p and PCAT6. (B) The level of miR-330-5p was detected using qRT-PCR assay in A549 and H1975 cells. **P<0.01 compared with control, Student’s t-test. (C) The levels of miR-330-5p in miR-330-5p overexpressing A549 and H1975 cells were determined by qRT-PCR. **P<0.01 compared with control, Student’s t-test. (D) The expressions of PCAT6 in miR-330-5p overexpressing A549 and H1975 cells were determined by qRT-PCR. **P<0.01 compared with control, Student’s t-test. (E) wt-PCAT6 or mut-PCAT6 was transfected into 293 T cell combination with miR-330–5p. The luciferase activity was measured. **P<0.01 compared with miR-ctr+wt-PCAT6, Student’s t-test. (F) The association between PCAT6 and miR-330-5p in NSCLC tissues was analyzed using qRT-PCR assay.

Abbreviations: NSCLC, non-small-cell lung carcinoma; PCAT6, prostate cancer-associated transcript 6; qRT-PCR, quantitative real-time polymerase chain reaction.